Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | PPID | Q08752 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7440971 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2MMP8MEN1KMT2APPID | |
| SCHEMBL2226 | 0.82 | MYC (0.46) | SMN1; SMN2MMP8ALDH1A1FFAR1 | |
| SCHEMBL16839699 | 0.81 | KCNQ2 (0.49) | SMN1; SMN2KMT2AFFAR1MAPK1 | |
| SCHEMBL16839005 | 0.81 | MKNK1 (0.44) | HDAC1PPIDLMNA | |
| SCHEMBL16838990 | 0.81 | MAPK1 (0.48) | SMN1; SMN2MMP8MEN1KMT2AHDAC1 | |
| SCHEMBL16839015 | 0.79 | MEN1 (0.42) | SMN1; SMN2MMP8MEN1KMT2APPID | |
| SCHEMBL16838997 | 0.78 | ALDH1A1 (0.47) | SMN1; SMN2MMP8MEN1KMT2AALDH1A1 | |
| SCHEMBL12894961 | 0.77 | PPID (0.58) | SMN1; SMN2MEN1KMT2AHDAC1PPID | |
| SCHEMBL2171018 | 0.77 | PPID (0.66) | SMN1; SMN2MMP8PPIDALDH1A1RECQL | |
| SCHEMBL24241874 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2MMP8MEN1KMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | SMN1; SMN2 2832/4885MMP8 2565/4885MEN1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.